Get started
Author

Qing Zhang

A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al. · Cancer Research · 17
PDF
Gas Vesicle-Assisted Ultrasound Imaging for Effective Anti-Tumour CAR-T Cell Immunotherapy Efficacy in Mice Model
2025 · Yizhen Huang, Zhao Yin, et al. · International Journal of Nanomedicine · 9
PDF
959P Phase I study of ARX305, a novel anti-CD70 antibody-drug conjugate, in advanced solid tumor
2025 · R-H. Xu, D. Ye, et al. · Annals of Oncology
Table S7 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S4 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Data from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S2 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Supplementary Data from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Data from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S3 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S5 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S4 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S1 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S6 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Supplementary Data from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S1 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S3 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S7 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S2 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S6 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Table S5 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma
2023 · Jing Shi, Tao Jiao, et al.
Targeting Nuclear Pore Complex to Radiosensitize Glioblastoma Stem Cells
2022 · K. Yang, S. Ci, et al. · International Journal of Radiation Oncology*Biology*Physics
Works count: 22
Citation count: 26
H-index: 2
I10-index: 1
Year
Topic
Type